Skip to content

Albino J. Oliveira‐maia

Champalimaud Foundation

4 papers in the library · 32 citations · publishing 2021-2025

Papers

Concomitant use of antidepressants and classic psychedelics: A scoping review

Journal of Psychopharmacology September 12, 2025 Stephan Tap, Kelan Thomas, Tomáš Páleníček et al. 5 citations

Classic psychedelics like psilocybin are being studied for psychiatric disorders. Current protocols typically require patients to stop antidepressants (ADs) for at least two weeks before psychedelic use to avoid serotonin syndrome and preserve efficacy, but discontinuation can worsen depression and increase suicidal ideation. This scoping review of 18 studies found that using ADs alongside classic psychedelics is generally safe and tolerable, with no increased risk of serotonin syndrome, especially with psilocybin. Some studies showed significant improvements in depression and other symptoms. Although some evidence suggests a potential reduction in acute subjective psychedelic effects, this was not consistent. The authors conclude that maintaining ADs may improve patient access and avoid discontinuation risks.

DOI: 10.1177/02698811251368360

Reply: Variability in motor threshold

Brain stimulation October 5, 2021 Gonçalo Cotovio, Albino J. Oliveira‐maia, Carter Paul et al. 3 citations

Transcranial direct current stimulation (tDCS) applied to the left dorsolateral prefrontal cortex does not reduce depressive symptoms more than sham stimulation in patients with treatment-resistant depression. In a randomized controlled trial, both active and sham tDCS groups showed similar improvements in depression scores over six weeks, with no significant difference between them. The findings suggest that tDCS, as administered in this protocol, is not effective as a standalone treatment for this population.

DOI: 10.1016/j.brs.2021.09.012 Scopus Depression economics Psychology Randomized controlled trial +7